VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.
Secarna Pharmaceuticals presents promising additional preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at AACR Annual Meeting 2026
- SECN-15 constitutes promising new therapeutic option by enhancing anti-tumor immunity and overcoming resistance to checkpoint inhibitors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting
- New findings underline reprogramming mechanism in tumoral endothelial cells from angiogenic to immune-permissive, interferon-responsive state through NRP1 knockdown activity
Martinsried (Munich), Germany, April 17, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that additional preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, USA, on Monday, April 20, 2026.
Would you like to keep up to date with the latest from Secarna Pharmaceuticals?
Click here to subscribe here to receive regular updates:
Latest News & Events
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.
Secarna Pharmaceuticals presents promising additional preclinical and translational data on proprietary antisense oligonucleotide SECN-15 at AACR Annual Meeting 2026
- SECN-15 constitutes promising new therapeutic option by enhancing anti-tumor immunity and overcoming resistance to checkpoint inhibitors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting
- New findings underline reprogramming mechanism in tumoral endothelial cells from angiogenic to immune-permissive, interferon-responsive state through NRP1 knockdown activity
Martinsried (Munich), Germany, April 17, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced that additional preclinical data for its proprietary antisense oligonucleotide (ASO) SECN-15 will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, USA, on Monday, April 20, 2026.